26.10.2012 Views

Abstract Book 2010 - CIMT Annual Meeting

Abstract Book 2010 - CIMT Annual Meeting

Abstract Book 2010 - CIMT Annual Meeting

SHOW MORE
SHOW LESS

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

030 Brix | Immune monitoring<br />

MHC Dextramers: improved detection of antigen-specific T-cells<br />

in fluid samples and in situ<br />

Liselotte Brix, Tina Jakobsen, and Henrik Pedersen<br />

Immudex, Copenhagen, Denmark<br />

Sensitive and reliable monitoring of cellular immune<br />

responses is becoming increasingly important in<br />

vaccine and immunotherapeutic development.<br />

Flow analysis using fluorescent MHC multimers<br />

has made a great impact in this field enabling visualization,<br />

enumeration and phenotypic characterization<br />

of antigen specific T-cells. Here we discuss<br />

how MHC Dextramers, a new generation of MHC<br />

multimer reagents, can be used for advanced detection<br />

of antigen specific T-cells in comprehensive<br />

applications.<br />

MHC Dextramer reagents carry a higher number<br />

of MHC-molecules and more fluorochromes than<br />

conventional MHC multimers. This increases their<br />

avidity for the specific T-cell and enhances their<br />

staining intensity, thereby increasing resolution and<br />

the signal-to-noise ratio. Furthermore the dextran<br />

backbone of the MHC Dextramer stabilizes the attached<br />

MHC-molecules and fluorochrome proteins.<br />

This allows specialized applications such as in situ<br />

staining (e.g. detection of antigen-specific T-cells<br />

in frozen tissue sections), detection of very rare<br />

events, combined staining with high numbers of<br />

MHC Dextramer reagents in same tube and MHC<br />

Dextramer staining combined with extracellular<br />

and intracellular staining for e.g. surface proteins<br />

and cytokines.<br />

Such specialized applications are useful in improving<br />

immune monitoring of cancer immunotherapeutics.<br />

71

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!